SPECIFIC MECHANISMS OF THROMBOSIS FORMATION AT PH-NEGATIVE MYELOPROLIFERATIVE NEW FORMATIONS

A. N Serbin

doi:10.17816/rmmar43397

Russian Military Medical Academy Reports ›› 2020, Vol. 39 ›› Issue (1-1S) :151 -154. DOI: 10.17816/rmmar43397

Articles

research-article

SPECIFIC MECHANISMS OF THROMBOSIS FORMATION AT PH-NEGATIVE MYELOPROLIFERATIVE NEW FORMATIONS

A. N Serbin

Author information +

History +

PDF

Abstract

The most relevant Ph-negative myeloproliferative neoplasms (MPN) include: polycythemia vera (PI), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Thrombosis and thromboembolism currently remain the main cause of disability and mortality in MPN. Most modern methods of specific cytoreductive therapy for MPN do not significantly affect the incidence of thrombotic complications, and in some cases may even contribute to their development. Therefore, the use of antithrombotic, primarily antiplatelet, therapy remains the most effective direction of prevention. Currently, various anticoagulants are becoming more common. For their introduction into hematological practice, a clear understanding of the formation of specific mechanisms of pathological thrombosis in MPN is necessary. To this end, we analyzed the disease-specific pathogenetic mechanisms of "thrombophilia" in various Ph-negative MPN.

Keywords

Ph-negative myeloproliferative neoplasms / MPN / polycythemia vera / essential thrombocythemia / primary myelofibrosis / thrombosis / thromboembolism

Cite this article

Download citation ▾

A. N Serbin. SPECIFIC MECHANISMS OF THROMBOSIS FORMATION AT PH-NEGATIVE MYELOPROLIFERATIVE NEW FORMATIONS. Russian Military Medical Academy Reports, 2020, 39(1-1S): 151-154 DOI:10.17816/rmmar43397

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	1. Меликян, А.Л. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний / А.Л. Меликян, А.Г. Туркина, К.М. Абдулкадыров [и др.] // Гематология и трансфузиология. - 2014. - №4(59). - С.31-56.

[2]	2. Поляков, А.С. Новые подходы к терапии классических Ph-негативных миелопролиферативных новообразований: опыт раннего при-менения цепэгинтерферона альфа А-2B / А.С. Поляков, Я.А. Носков, В.В. Тыренко [и др.] // Онкогематология. - 2018. - №1(13). - С.29-44.

[3]	3. Диагностика и лечение Ph-негативных миелопролиферативных новообразований в Военно-медицинской академии имени С.М. Кирова: Методические рекомендации и локальный протокол лечения / Под ред. В.В. Тыренко. - СПб.: ВМедА, 2019. - 84 с.

[4]

4. Borowczyk, M. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in pa-tients with Philadelphia-negative myeloproliferative neoplasms / M. Borowczyk, M. Wojtaszewska, K. Lewandowski [et al.] // Thrombosis Re-search. - 2015. - №135(2). - С.272-280.

[5]	5. Guadall, A. Endothelial cells harbouring the JAK2V617F mutation display pro-adherent and pro-thrombotic features / A. Guadall, E. Lesteven, G. Letort [et al.] // Thromb. Haemost. - 2018. - №118(9). - С.1586-1589.

[6]	6. Guy, A. La thrombose au cours des ne oplasies mye loprolife ratives / A. Guy, C. James // Me decine/sciences. - 2019. - №35(8-9). - С.651-658.

[7]	7. Tong, D. Phosphatidylserine-exposing blood and endothelial cells contribute to the hypercoagulable state in essential thrombocythemia patients / D. Tong, M. Yu, L. Guo [et al.] // Ann. Hematol. - 2018. - №97(4). - С.605-616.

[8]	8. Vannucchi, A.M. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden / A.M. Vannucchi, P. Guglielmelli, G. Longo [et al.] // Leukemia. - 2007. - №21(9). - С.1952-1959.